Yi Li

8017112, Sep 13, 2011

May 9, 2006

11/431290

Yi Li - Canton MI, US
Michael Chopp - Southfield MI, US

Henry Ford Health System - Detroit MI

C12N 5/071
C12N 5/0797
C12N 5/22

424 937, 435377

The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS).

20050158397, Jul 21, 2005

Jan 14, 2003

10/502723

Michael Chopp - Southfield MI, US
Yi Li - Canton MI, US
Xiaoguang Chen - Madison Heights MI, US

A61K035/30
A61K035/00
C12P021/04

424570000, 424115000, 424093700, 435070300

A therapeutic for use in inducing angiogenesis and vasculogenesis, the therapeutic including angiogenesis and vasculogenesis inducing factors isolated from stem cells in conjunction with a pharamaceutically acceptable cell therapy. A method of amplifying the production of angiogenesis and vasculogenesis inducing factors secreted by exposing stem cells to and co-culturing the stem cells with a compound for increasing the production of angiogenesis and vasculogenesis inducing factors. Angiogenesis and vasculogenesis inducing factors isolated and purified from stem cells for use in a therapy. A process for obtaining the angiogenesis and vasculogenesis inducing factors as set forth above, the process including the steps of isolating and purifying human mesenchymal stem cells from tissue prior to differentiation and then culture expanding the mesenchymal stem cells to produce a tool for neurological and musculoskeletal therapy. Isolated and culture expanded mesenchymal stem cells under the influence of a requisite compound, that are capable of differentiating and producing a desired cell phenotype needed for tissue repair.

20050169896, Aug 4, 2005

Dec 30, 2004

11/027881

Yi Li - Canton MI, US
Michael Chopp - Southfield MI, US

A61K045/00

424093700

The present invention relates to a treatment of neural injury and neurodegenerative diseases. Also included in the present invention is the use of stromal cells for the treatment of neural injury (stroke, traumatic brain injury, spinal cord injury) and neurodegeneration (i.e. Parkinson's disease).

20090162327, Jun 25, 2009

Oct 10, 2008

12/249687

Yi Li - Canton MI, US
Michael Chopp - Southfield MI, US

THERADIGM, INC. - Sunnyvale CA

A61K 35/12

424 937

There is provided a treatment for patients suffering from neurodegenerative disease or neural injury including the steps of transplanting cultured bone marrow cells into the spinal cord or brain or injecting intravascularly bone marrow cells of a patient in need. Also provided is a method of activating the differentiation of neural cells in an injured brain including the steps of transplanting bone marrow cells adjacent to the injured brain cells and activating the endogenous central nervous system stem cells to differentiate into neurons. A method of treating injured brain or spinal cord cells is also provided including the steps of transplanting bone marrow cells near the injured brain cells and generating new neurons at the location of transplantation. A method of treating injured brain or spinal cord cells with a composite of MSCs and neurospheres.

20090169527, Jul 2, 2009

Dec 29, 2008

12/345385

Michael Chopp - Southfield MI, US
Yi Li - Canton MI, US
Xiaoguang Chen - Madison Heights MI, US

HENRY FORD HEALTH SYSTEM - Detroit MI

A61K 45/00
C12N 5/08
A61P 9/02

424 937, 435375

A therapeutic for use in inducing angiogenesis and vasculogenesis, the therapeutic including angiogenesis and vasculogenesis inducing factors isolated from stem cells in conjunction with a pharmaceutically acceptable cell therapy. A method of amplifying the production of angiogenesis and vasculogenesis inducing factors secreted by exposing stem cells to and co-culturing the stem cells with a compound for increasing the production of angiogenesis and vasculogenesis inducing factors. Angiogenesis and vasculogenesis inducing factors isolated and purified from stem cells for use in a therapy. A process for obtaining the angiogenesis and vasculogenesis inducing factors as set forth above, the process including the steps of isolating and purifying human mesenchymal stem cells from tissue prior to differentiation and then culture expanding the mesenchymal stem cells to produce a tool for neurological and musculoskeletal therapy. Isolated and culture expanded mesenchymal stem cells under the influence of a requisite compound, that are capable of differentiating and producing a desired cell phenotype needed for tissue repair.

20120195865, Aug 2, 2012

Jul 26, 2011

13/190811

Yi Li - Canton MI, US
Michael Chopp - Southfield MI, US

HENRY FORD HEALTH SYSTEM - Detroit MI

A61K 35/28
A61P 25/28
A61K 48/00

424 9321, 424 937

The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS).

20180259349, Sep 13, 2018

May 16, 2018

15/981418

- Plano TX, US
Yi Li - Ann Arbor MI, US
Hideki HADA - Ann Arbor MI, US
Miles J. JOHNSON - Ann Arbor MI, US

TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. - Plano TX

G01C 21/34
G01C 21/36

The virtual reality navigation system can display the position of an autonomous vehicle at a predetermined amount of time in the future via virtual reality. A virtual reality display can display a virtual reality autonomous vehicle, as if the virtual reality autonomous vehicle is the autonomous vehicle operating at the predetermined amount of time in the future. Additionally, a virtual reality interface can provide an interface for an operator to interact with the environment of the autonomous vehicle. The virtual reality interface can receive an alternate route selection, and display in virtual reality the one or more maneuvers that would be required to reach the selection.

20180222490, Aug 9, 2018

Feb 9, 2017

15/428379

- Erlanger KY, US
Yi Li - Ann Arbor MI, US
Kazutoshi Ebe - Novi MI, US

B60W 50/14
B60K 35/00
B60R 1/00
B60Q 3/82
B60Q 3/74
B60Q 1/26
B60Q 1/34
B60N 2/22
B60N 2/02
B60N 2/14
B60W 40/08
G05D 1/00
G06K 9/00
G06T 7/70

System, methods, and other embodiments described herein relate to adaptively communicating notices to passengers within a vehicle. In one embodiment, a method includes in response to receiving a notice about an occurrence of an event, determining a viewing orientation of a passenger in the vehicle according to at least one electronic input that indicates information about a physical position of the passenger within the vehicle. The event is an incident associated with the vehicle for which the passenger is to be informed. The method also includes selecting at least one alerting device from available communication devices in the vehicle according to the viewing orientation by determining which of the available communication devices correspond with the viewing orientation of the passenger. The method further includes controlling the at least one alerting device to communicate the notice to the passenger about the occurrence of the event.